Later Use

This debate will examine the optimal timing of lutetium-PSMA therapy in the management of metastatic prostate cancer with a review of clinical trial evidence, patient selection criteria, and outcomes associated with different sequencing strategies. The discussion will address potential benefits of earlier intervention versus reserving lutetium-PSMA for more advanced disease stages. Our presenters will provide expert insight into how timing considerations may influence treatment outcomes in metastatic prostate cancer. Faculty will provide an overview of evidence supporting the use of lutetium-PSMA after progression on standard systemic therapies, including androgen receptor-targeted agents and chemotherapy. Discussion will address expected efficacy and management of treatment-related toxicities in heavily pretreated populations, leading participants to new perspective on how lutetium-PSMA fits into established sequencing strategies.